Impact BioMedical Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $32KTTM through 31 Dec 2025
Net Income -$11.8MTTM through 31 Dec 2025
Free Cash Flow -$1.9MTTM through 31 Dec 2025
Margins
| Current | |
|---|---|
| Operating Margin | -13,381.3% |
| Net Margin | -36,993.8% |
Returns
-119.7%ROE
-18.7%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio0.35x
Net Debt-$3Knet cash position
Cash & Equivalents$3K
Quality Metrics
FCF Margin-5,937.5%
Dividend
No dividend
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Biotechnology | $32K | View detailsThe company operates as a single business segment focused on drug discovery and open-air defense initiatives. Near-term outlook is heavily dependent on the pending reverse merger with Dr. Ashley's Limited to establish commercial pharmaceutical manufacturing capabilities. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.